Bacterial nucleic acid synthesis machinery

The bacterial nucleic acid synthesis machinery is a complex and highly coordinated system of enzymes and proteins responsible for the replication, repair, and transcription of the bacterial genome. This machinery includes the replisome, which carries out DNA replication, and the transcription apparatus, centered around DNA-directed RNA polymerase. Key enzymatic components such as DNA gyrase and topoisomerase IV manage the topological state of DNA, ensuring that supercoiling and catenation do not impede cellular processes [1, 6]. Additionally, the machinery relies on the synthesis of nucleotide precursors, which are produced through pathways such as the folate cycle [10, 14]. Because these bacterial enzymes possess structural and functional differences from their eukaryotic counterparts, they serve as ideal targets for selective antimicrobial therapy [13]. Antibiotics like fluoroquinolones, rifamycins, and fidaxomicin exploit these differences to disrupt essential genetic processes, leading to bacteriostatic or bactericidal effects. Fluoroquinolones target topoisomerases to induce lethal DNA double-strand breaks, while rifamycins and fidaxomicin bind RNA polymerase to block the initiation of transcription [3, 13]. Antifolate drugs like sulfonamides and trimethoprim indirectly halt nucleic acid production by starving the machinery of necessary precursors [10, 14]. This target remains a primary focus for drug development, particularly in the effort to overcome emerging antibiotic resistance in pathogenic bacteria [2, 4].

Other names

Bacterial DNA synthesis machineryBacterial replisomeBacterial transcription machineryBacterial nucleic acid synthesis apparatusBacterial DNA replication machinery

Drugs targeting the bacterial nucleic acid synthesis machinery primarily act by inhibiting key enzymes involved in DNA replication and transcription. Fluoroquinolones and quinolones bind to the DNA-enzyme complex of DNA gyrase and topoisomerase IV, preventing the religation of DNA strands and leading to lethal double-strand breaks [6, 13]. Rifamycins bind to the beta-subunit of bacterial DNA-directed RNA polymerase, sterically blocking the initiation and elongation of the nascent RNA chain and thus halting transcription [3, 13]. Fidaxomicin also inhibits RNA polymerase but specifically targets the sigma subunit-dependent initiation of transcription [13]. Additionally, antifolate drugs like sulfonamides and trimethoprim inhibit the synthesis of tetrahydrofolate, a critical cofactor for the production of purines and thymidylate, thereby indirectly starving the machinery of necessary nucleotide precursors [10, 14].